Hydroxyurea to inhibit human immunodeficiency virus-1 replication

Pharmacotherapy

Volumn 19, Issue 2, 1999, Pages 196-204

  Romanelli, Frank ^a   Pomeroy, Claire ^b   Smith, Kelly M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD4 ANTIGEN; DIDANOSINE; ENZYME INHIBITOR; HYDROXYUREA; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; VIRUS REPLICATION;

EID: 0032963053     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.3.196.30913     Document Type: Review

References (39)

1. Anonymous. Update: trends in AIDS incidence - United States, 1996. MMWR 1997;46:861-7.
2. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1998;280:78-86.
3. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
4. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338: 1281-92.
5. Cohen J. HIV suppressed long after treatment. Science 1997;277:1927.
6. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-4.
7. Gao W, Johns DG, Mitsuya H. Human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2,3-dideoxynucleosides. Molec Pharmacol 1994;46:767-72.
8. Bristol-Myers Squibb. Droxia package insert. Princeton, NJ;1998.
9. Zachary KC, Davis B. Hydroxyurea for HIV infection. AIDS Clin Care 1998;10:25-7.
10. Balzarini J, Cooney DA, Dalal M, et al. 2,3-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Molec Pharmacol 1987; 32:798-806.
11. Gao W, Johns DG, Chokekijchai S, et al. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2,3-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
12. Palmer S, Cox S. Increased activation of the combination of 3-azido-3-deoxythymidine and 2-deoxy-3-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother 1997;41:460-4.
13. Bianchi V, Borella S, Calderazzo F, et al. Inhibition of ribonucleotide reductase by 2-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl. Acad Sci USA 1994;91:8403-7.
14. De Antoni A, Foli A, Lisziewicz J. Mutations in the pol gene of human immunodeficiency virus type I in infected patients receiving ddI and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
15. Gao W, Cara A, Gallo R, et al. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
16. Malley SD, Grange JM, Hamdei-Sangsari F, et al. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxyamate compounds with 2,3-dideoxyinosine in infected resting lymphocytes. Proc Natl Acad Sci USA 1994;91: 11017-21.
17. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of ddI and hydroxyurea in HIV-1-infected individuals. J Acquir Immun Defic Syndr Hum Retrovir 1995;10:36-40.
18. Montaner J, Zala C, Raboud J, et al. A pilot study of hydroxyurea as adjuvant therapy among patients with advanced HIV disease receiving ddI therapy. Presented at the 3rd conference on retroviruses and opportunistic infections, Washington, DC, Jan 28-Feb 1, 1996.
19. Vila J, Biron F, Nugier F, et al. 1-Year follow-up to the use of hydroxycarbamide and ddI in HIV infection [letter]. Lancet 1996;348:203-4.
20. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with ddI and hydroxycarbamide [letter]. Lancet 1997;350:635-6.
21. Lafeuillade A, Pellegrino P, Poggi C, et al. Hydroxyurea and HIV [letter]. AIDS 1995;9:1290-1.
22. Simonelli C, Nasti G, Vaccher E, et al. Hydroxyurea treatment in HIV-infected patients [letter]. J Acquir Immun Defic Syndr Hum Retrovir 1996;13:462-4.
23. Lori F, Jessen H, Foli A, et al. Long-term suppression of HIV-1 by hydroxyurea and ddI [letter]. JAMA 1997;277:1437-8.
24. Lori F, Malykah AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retrovir 1997;13:1403-9.
25. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic ddI therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6.
26. Rutschmann OT, Opravil M, Iten A, et al. ddI and d4T with or without hydroxyurea for HIV-1 infection [abstr]. Presented at the 5th conference on retroviruses and opportunistic infections, Chicago, Feb 1-5, 1998.
27. Rossero R, McKinsey D, Green S, et al. Open label combination therapy with stavudine, ddI, and hydroxyurea in nucleoside experienced HIV-1 infected patients [abstr]. Presented at the 5th conference on retroviruses and opportunistic infections, Chicago, Feb 1-5, 1998.
28. Galpin JE, Lori F, Globe DR, et al. Safety, sheltering, and synergy of hydroxyurea (HU) with ddI or ddI plus d4T in HIV-infected patients [abstr]. Presented at the 5th conference on retroviruses and opportunistic infections, Chicago, Feb 1-5, 1998.
29. Lori F, Jessen H, Clerici M, et al. Consistent, sustained HIV suppression without rebound by hydroxyurea, ddI and a protease inhibitor prevents loss of immunologic functions [abstr]. Presented at the 5th conference on retroviruses and opportunistic infections, Chicago, Feb 1-5, 1998.
30. Federici ME, Lupo S, Cahn P, et al. Hydroxyurea in combination regimens for the treatment of antiretroviral naïve HIV-infected adults [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
31. Miles S, Winters RE, Ruane WP, et al. Salvage of multi-drug resistant HIV infection with D4T/3TC/hydroxyurea [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
32. Yerly SO, Rutschmann F, Marchal M, et al. Assessment of viral load and CD4/CD8 ratio in blood and lymph nodes in patients treated with D4T, ddI, plus or minus hydroxyurea [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
33. Rusnak J, Berry A, Stinette B, et al. DDI once/day versus twice daily alone and also with hydroxyurea once/day [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
34. Lori F, Jessen H, Clerici M, et al. Suppression of HIV replication and cell proliferation leads to minimal levels of proviral DNA and to immune recovery [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
35. Jaegel-Geudes E, Wolf S, Goeppner I, et al. D4T/ddI plus hydroxyurea - an alternative to a PI containing triple regimen in ART-naïve HIV + patients [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
36. Seminari E, Maserti R, Lori F, et al. Long term suppression of HIV with a simple, non-toxic, inexpensive combination of ddI plus hydroxyurea [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
37. Back DJ, Hoggard KPJ, Henery-Mowatt JS, et al. Enhanced activation of nucleoside analogs in the presence of hydroxyurea [abstr]. Presented at the 12th world AIDS conference, Geneva, June 30, 1998.
38. Feinberg MB, Carpenter C, Fauci A, et al. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults. Ann Intern Med 1998;128:1057-1100.
39. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics, 1998.